Home / Business and Economy / Lord's Mark Eyes Global Growth With New Medical Tech

Lord's Mark Eyes Global Growth With New Medical Tech

Summary

  • Net profit of ₹82.01 crore in H1 FY27, exceeding FY26 full-year profit.
  • Revenue reached ₹718.77 crore in H1 FY27, surpassing FY26 figures.
  • Expansion into US, UK, and Caribbean markets planned for early 2027.

Lord's Mark Industries has announced a robust financial performance for the first half of FY27, achieving a consolidated net profit of ₹82.01 crore. This figure nearly doubles its entire profit from FY26, with revenues climbing to ₹718.77 crore, already exceeding the previous fiscal year's total.

The company is strategically expanding its operations, with plans to launch advanced medical technologies. These include AI-powered dialysis machines and Sickle Cell screening devices, slated for release by early 2027. Significant market expansion is also underway in the US, UK, and Caribbean.

Further growth initiatives include commencing commercial shipments of AI-based dialysis machines by December 2026, with export orders secured. January 2027 will see the launch of Sickle Cell screening and breast cancer screening devices. UK operations are set to begin in February 2027, with US sales targeting March 2027, pending FDA approval.

The company is also investing in its manufacturing capabilities, with a third IVD facility expected by March 2028. Expansion of its institutional healthcare network aims to serve 25,000 customers by the same date. Lord's Mark is also pursuing global reach for its proprietary CAR-T cancer treatment technology.

Disclaimer: This story has been auto-aggregated and auto-summarised by a computer program. This story has not been edited or created by the Feedzop team.

Read more news on

Property Code: 5571